Exploring the ramifications of the Federal Circuit’s first decision interpreting 35 USC 102 as amended by the AIA: Helsinn Healthcare v. Teva Pharms" and " Impact of the Federal Circuit’s decision in Novartis v. Noven upholding the invalidation by the PTAB